{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:12:37Z","timestamp":1792696357644,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Defects in expression, maturation or function of the epithelial membrane glycoprotein CFTR are causative for the progressive disease cystic fibrosis. Recently, molecular therapeutics that improve CFTR maturation and functional defects have been approved. We aimed to verify whether we could detect an improvement of CFTR protein expression and maturation by triple therapy with elexacaftor-tezacaftor-ivacaftor (ELX\/TEZ\/IVA).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Rectal suction biopsies of 21 p.Phe508del homozygous or compound heterozygous CF patients obtained pre- and during treatment with ELX\/TEZ\/IVA were analyzed by CFTR Western blot that was optimized to distinguish CFTR glycoisoforms.<\/jats:p><jats:p><jats:bold>Findings:<\/jats:bold> CFTR western immunoblot analysis revealed that\u2014compared to baseline\u2014the levels of CFTR protein increased by at least twofold in eight out of 12 patients upon treatment with ELX\/TEZ\/IVA compared to baseline (<jats:italic>p<\/jats:italic> &amp;lt; 0.02). However, polydispersity of the mutant CFTR protein was lower than that of the fully glycosylated wild type CFTR Golgi isoform, indicating an incompletely glycosylated p.Phe508el CFTR protein isoform C* in patients with CF which persists after ELX\/TEZ\/IVA treatment.<\/jats:p><jats:p><jats:bold>Interpretation:<\/jats:bold> Treatment with ELX\/TEZ\/IVA increased protein expression by facilitating the posttranslational processing of mutant CFTR but apparently did not succeed in generating the polydisperse spectrum of N-linked oligosaccharides that is characteristic for the wild type CFTR band C glycoisoform. Our results caution that the lower amounts or immature glycosylation of the C* glycoisoform observed in patients\u2019 biomaterial might not translate to fully restored function of mutant CFTR necessary for long-term provision of clinical benefit.<\/jats:p>","DOI":"10.3389\/fphar.2023.1114584","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:10:31Z","timestamp":1674796231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Frauke","family":"Stanke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia T.","family":"Pallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Hedtfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella M.","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Minso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauer-Heilborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"259002","DOI":"10.1242\/jcs.259002","article-title":"Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs","volume":"135","author":"Abu-Arish","year":"2022","journal-title":"J. Cell Sci. jcs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcf.2006.09.002","article-title":"Endocytic trafficking of CFTR in health and diseases","volume":"6","author":"Ameen","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B4","first-page":"191","article-title":"Decreased expression of the CFTR protein in remodeled human nasal epithelium from non-cystic fibrosis patients","volume":"72","author":"Brezillon","year":"1995","journal-title":"Lab. Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1172\/JCI12108","article-title":"Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings","volume":"108","author":"Bronsveld","year":"2001","journal-title":"J. Clin. Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/ijms22105262","article-title":"Partial rescue of F508del-CFTR stability and trafficking defects by double corrector treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/01.lab.0000022221.88025.43","article-title":"Polarized expression of cystic fibrosis transmembrane conductance regulator and associated epithelial proteins during the regeneration of human airway surface epithelium in three-dimensional culture","volume":"82","author":"Castillon","year":"2002","journal-title":"Lab. Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1242\/jcs.028951","article-title":"Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator","volume":"121","author":"Chang","year":"2008","journal-title":"J. Cell Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1183\/13993003.01192-2015","article-title":"Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids","volume":"48","author":"Dekkers","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1002\/hep.510290634","article-title":"Analytic approaches for the evaluation of costs","volume":"29","author":"Dray-Charier","year":"1999","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"C990","DOI":"10.1152\/ajpcell.1994.267.4.C990","article-title":"Salt stress increases abundance and glycosylation of CFTR localized at apical surfaces of salt gland secretory cells","volume":"267","author":"Ernst","year":"1994","journal-title":"Am. J. Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1091\/mbc.E04-03-0176","article-title":"Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator","volume":"15","author":"Gentzsch","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.cell.2011.07.021","article-title":"Rescue of \u0394F508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway","volume":"146","author":"Gee","year":"2011","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1165\/rcmb.2016-0276MA","article-title":"Pharmacological rescue of conditionally reprogrammed cystic fibrosis bronchial epithelial cells","volume":"56","author":"Gentzsch","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"628722","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway epithelial inflammation in vitro augments the rescue of mutant CFTR by current CFTR modulator therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1083\/jcb.200808124","article-title":"N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic","volume":"184","author":"Glozman","year":"2009","journal-title":"J. Cell Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1091\/mbc.E18-04-0252","article-title":"Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: Biogenesis versus degradation","volume":"30","author":"Gong","year":"2019","journal-title":"Mol. Biol. Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e121159","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1172\/JCI5731","article-title":"DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis","volume":"103","author":"K\u00e4lin","year":"1999","journal-title":"J. Clin. Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"166955","DOI":"10.1016\/j.jmb.2021.166955","article-title":"Co-translational folding of the first transmembrane domain of ABC-transporter CFTR is supported by assembly with the first cytosolic domain","volume":"433","author":"Kleizen","year":"2021","journal-title":"J. Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1091\/mbc.e04-11-1010","article-title":"Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia","volume":"16","author":"Kreda","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev.biochem.76.061005.092322","article-title":"Glycosyltransferases: Structures, functions, and mechanisms","volume":"77","author":"Lairson","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"L719","DOI":"10.1152\/ajplung.00431.2015","article-title":"Trafficking and function of the cystic fibrosis transmembrane conductance regulator: A complex network of posttranslational modifications","volume":"311","author":"McClure","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/glycob\/10.11.1225","article-title":"Characterization of the oligosaccharide structures associated with the cystic fibrosis transmembrane conductance regulator","volume":"10","author":"O\u2019Riordan","year":"2000","journal-title":"Glycobiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature15729","article-title":"F508 CFTR interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological modulation of ion channels for the treatment of cystic fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","article-title":"DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers","volume":"23","author":"Rowe","year":"2010","journal-title":"Pul. Pharm. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/s0021-9258(18)46056-5","article-title":"Biochemical characterization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis epithelial cells","volume":"267","author":"Sarkadi","year":"1992","journal-title":"J. Biol. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"23256","DOI":"10.1038\/s41598-021-02420-x","article-title":"Nonspecific binding of common anti-CFTR antibodies in ciliated cells of human airway epithelium","volume":"11","author":"Sato","year":"2021","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","article-title":"Global view of human protein glycosylation pathways and functions","volume":"21","author":"Schjoldager","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1203\/00006450-200211000-00005","article-title":"Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation","volume":"52","author":"Sermet-Gaudelus","year":"2002","journal-title":"Pediatr. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells","volume":"58","author":"Sette","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"36762","DOI":"10.1074\/jbc.M508944200","article-title":"The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells","volume":"280","author":"Swiatecka-Urban","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbadis.2010.08.001","article-title":"Functional analysis of F508del CFTR in native human colon","volume":"1802","author":"van Barneveld","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e57617","DOI":"10.1371\/journal.pone.0057617","article-title":"Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis","volume":"8","author":"van Meegen","year":"2013","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"22578","DOI":"10.1074\/jbc.M401522200","article-title":"Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines","volume":"279","author":"Varga","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e1002462","DOI":"10.1371\/journal.pbio.1002462","article-title":"Ribosomal stalk protein silencing partially corrects the df508-CFTR functional expression defect","volume":"14","author":"Veit","year":"2016","journal-title":"PLoS Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.3390\/ijms22147590","article-title":"CFTR lifecycle map-A systems medicine model of CFTR maturation to predict possible active compound combinations","volume":"22","author":"Vinhoven","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"25710","DOI":"10.1016\/S0021-9258(18)47306-1","article-title":"Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins","volume":"269","author":"Ward","year":"1994","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"140792","DOI":"10.1016\/j.bbapap.2022.140792","article-title":"Opposite regulation of F508del-CFTR biogenesis by four poly-lysine ubiquitin chains in vitro","volume":"1870","author":"Wu","year":"2022","journal-title":"Biochim. Biophys. Acta Proteins Proteom"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1074\/jbc.M110263200","article-title":"Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway","volume":"277","author":"Yoo","year":"2002","journal-title":"J. Biol. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1114584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:10:35Z","timestamp":1674796235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1114584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":50,"alternative-id":["10.3389\/fphar.2023.1114584"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1114584","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"article-number":"1114584"}}